US pulls authorisation for GSK-Vir's Covid-19 therapy
Sign up now: Get ST's newsletters delivered to your inbox
Authorisation for the companies' sotrovimab therapy had already been pulled in much of the US north-east in March.
PHOTO: REUTERS
WASHINGTON (REUTERS) - The United States health regulator said on Tuesday (April 5) that GlaxoSmithKline and Vir Biotechnology's antibody therapy was no longer authorised as a Covid-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country.
The move by the agency, which had already pulled its authorisation for the sotrovimab therapy in much of the US north-east last month, sent shares in Vir Biotechnology 11.5 per cent lower.
The highly contagious BA.2 coronavirus sub-variant is estimated to make up about three of every four Covid-19 cases in the US, according to the latest government data.
GlaxoSmithKline and Vir have said treatment with sotrovimab retains neutralising activity against the BA.2 sub-variant, but others, including researchers from Columbia University, disagree.
Vir Biotechnology in a filing with the Securities and Exchange Commission said the two companies were preparing a package of data to support the use of a higher dose of sotrovimab for the Omicron BA.2 sub-variant, which will be shared with regulators globally, reiterating the companies' plan from last month.
Vir still expects to recognise about US$1.1 billion (S$1.5 billion) in collaboration revenue when sotrovimab doses are delivered in the first half of 2022.
The companies also plan to submit an application for full approval of the drug in the second half of the year, and expect to start two late-stage trials in the second quarter to assess whether sotrovimab can prevent symptomatic Covid-19 infection in immunocompromised patients, Vir said.
GSK spokesman Lyndsay Meyer said the company will continue to work with governments and health systems, and ensure ongoing access to sotrovimab.
